Hope for teens with down syndrome regression: three therapies put to the test
NCT ID NCT05662228
First seen Mar 09, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This study tests three medications—lorazepam, IVIG, and tofacitinib—in 66 people with Down syndrome (ages 8-30) who have developed a serious condition called Down Syndrome Regression Disorder (DSRD). DSRD causes sudden loss of skills, catatonia, and other severe symptoms. The goal is to see which treatment is safest and most effective at improving symptoms. Participants are randomly assigned to one of the three therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
Conditions
Explore the condition pages connected to this study.